15 December 2015 – Parsortix sales
The company has announced that it has made the first sales of its Parsortix system for research use in line with the strategy announced in July. The company is initially targeting sales to cancer research centres and believes that the addressable market is around £250m per annum. As well as generating revenues for the company research use sales also broaden the range of users and can result in new applications being found for the system. The shares remain a LONG TERM BUY.